Critical Outcome Technologies to Present at the 12th Annual BIO Investor Forum

Critical Outcome Technologies to Present at the 12th Annual BIO Investor Forum

ID: 302733

(firmenpresse) - LONDON, ONTARIO -- (Marketwired) -- 10/03/13 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Company"), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President & CEO, will be presenting at the 12th Annual BIO Investor Forum () on Wednesday, October 9, 2013, at 9:30 a.m. PDT in San Francisco.

Dr. Danter will highlight the Company's innovative drug discovery platform technology and two-pronged commercial validation and revenue strategy during the live presentation. Dr. Danter will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

An online investor kit, including the Company's investor presentation and fact sheet, are available on the Company's corporate blog at .

Follow (at)CriticalOutcome and the official conference feed on Twitter, and join the conversation by using #BIF13.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit .

Follow (at)CriticalOutcome on Twitter at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Critical Outcome Technologies Inc.




Dr. Wayne Danter
President & CEO
519-858-5157



Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Boston Therapeutics Closes $5.3 Million in Private Placement of Common Stock and Warrants Theratechnologies to Announce Third Quarter 2013 Financial Results
Bereitgestellt von Benutzer: Marketwired
Datum: 03.10.2013 - 13:00 Uhr
Sprache: Deutsch
News-ID 302733
Anzahl Zeichen: 0

contact information:
Town:

LONDON, ONTARIO



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 189 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Critical Outcome Technologies to Present at the 12th Annual BIO Investor Forum"
steht unter der journalistisch-redaktionellen Verantwortung von

Critical Outcome Technologies Inc. (COTI) (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Critical Outcome Technologies Closes Financing ...

LONDON, ONTARIO -- (Marketwired) -- 12/22/14 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Corporation") the biopharmaceutical company that uses machine learning to rapidly develop targe ...

Alle Meldungen von Critical Outcome Technologies Inc. (COTI)



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z